Patents by Inventor Kalet León Monzón
Kalet León Monzón has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11926654Abstract: The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the bi-cytokines gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. Pharmaceutical compositions comprising as an active ingredient the fusion proteins object of this patent are also described.Type: GrantFiled: March 5, 2019Date of Patent: March 12, 2024Assignee: CENTRO DE INMUNOLOGIA MOLECULARInventors: Tays Hernández García, Maura Lisett Rábade Chediak, Kalet León Monzón, Circe Mesa Pardillo, Luis Enrique Fernández Molina, Giselle Hevia Hernández
-
Publication number: 20240042013Abstract: This invention relates to the field of Biotechnology and Medicine. It describes the use of vaccine compositions based on the receptor binding domain of SARS-CoV-2 virus in the treatment of patients recovered from COVID-19 and in subjects vaccinated with vaccine platforms other than subunit vaccines, who fail to develop effective protective immunity or where immunity has decreased over time and a booster with the same vaccine used in primary vaccination is not recommended. Particularly, this use is described for vaccine compositions comprising a covalent conjugate of the receptor binding domain (RBD) and a carrier protein such as tetanus toxoid, diphtheria toxoid and diphtheria toxoid mutant CRM197, vaccine compositions having the RBD as antigen, with or without the immunopotentiator outer membrane vesicles of serogroup B Neisseria meningitidis.Type: ApplicationFiled: December 14, 2021Publication date: February 8, 2024Inventors: Vicente Guillermo Verez Bencomo, Yury Valdés Balbín, Dagmar GarcÍa Rivera, Rolando Ochoa Azze, Yanet Climent Ruiz, Humberto González Rodríguez, Ivette Orasa Vázquez, Mariannia Díaz Hernández, Belinda Sánchez Ramírez, Eduardo Ojito Magaz, Kalet León Monzón, Consuelo Milagro, Arturo Chang Monteagudo, Delia Esther Porto González, Marta Dubed Echeverría, Mireida Rodríguez Acosta
-
Publication number: 20230256069Abstract: The present invention is related to the fields of Biotechnology and Medicine. Particularly, it describes the use of epidermal growth factor (EGF) deprivation agents that contribute to lowering and/or depleting serum epidermal growth factor levels, which has implications in the treatment of the chronic obstructive pulmonary disease. These agents can be vaccine compositions comprising as active principle the conjugate between recombinant human EGF and a carrier protein.Type: ApplicationFiled: July 19, 2021Publication date: August 17, 2023Inventors: Amparo Emilia Macias Abraham, Tania Crombet Ramos, Kalet León Monzón, Danay Saavedra Hernández, Orestes Santos Morales, Elia Neninger Vinageras, Pedro Pablo Pino Alfonso, Jenysbel de la Caridad Hernandez Reyes, Mary Reid, Kelvin Lee
-
Patent number: 11718676Abstract: This invention provides new antibodies (Ab) and fragments that recognize the extracellular region of the human epidermal growth factor receptor (hEGFR) with a higher affinity than the Ab nimotuzumab, thus been able to recognize more efficiently lines with medium expression of EGFR. The present invention also relates to pharmaceutical compositions comprising as active principle the disclosed Abs and fragments and their use in the therapy of tumors with EGFR expression. In addition, it relates to the use of the Abs and fragments disclosed linked to a radioisotope or fluorophore for the localization of EGFR positive tumors. Additionally, the Abs and fragments disclosed can be used in the directionalization of the immune response to EGFR positive tumor cells when they are fused to protein or protein domains of immunological interest.Type: GrantFiled: November 20, 2018Date of Patent: August 8, 2023Assignee: CENTRO DE INMUMOLOGIA MOLECULARInventors: Yaima Tundidor Cabado, Gertrudis Rojas Dorantes, Kalet Leon Monzon
-
Publication number: 20230226163Abstract: The present invention is related to biotechnology, particularly to the field of human health. It provides new vaccine compositions that comprise as active principle a system that contains the recombinant human EGF, or peptides thereof, and a carrier protein or peptide, bound to a nucleus constituted by inorganic nanoparticles, with nanometric or submicrometric scale dimensions. These vaccine compositions are useful for the chronic treatment of cancer and have as advantages that their administration does not result in the appearance of adverse effects at the injection site and that they do not accumulate in the body.Type: ApplicationFiled: May 31, 2021Publication date: July 20, 2023Inventors: Gustavo González Ruiz, David Alejandro González Martínez, Fernando Bordallo León, Belinda Sánchez Ramírez, Kalet León Monzón, Yerandy Echeverría Luna, Maria del Carmen Luzardo Lorenzo, Mabel Cruz Rodríguez, Adys González Palomo, Julio Felipe Santo Tomás Pompa, Judey Aymed García Artalejo, Elaine Ruiz Castro, Lien López Matilla
-
Publication number: 20230151107Abstract: The present invention provides the use of anti-CD6 antibodies that specifically bind to domain 1 of CD6 for treating effects of a coronavirus or bacterial agent and particularly COVID-19 and variants thereof. The anti-CD6 antibodies of the present invention exhibit therapeutic activity by reducing the overactive immune response, such as the high expression levels of cytokines.Type: ApplicationFiled: March 3, 2021Publication date: May 18, 2023Inventors: Pradip NAIR, Jose Enrique Montero CASIMIRO, Kiran MAZUMDARSHAW, Usha BUGHANI, Sandeep Nilkanth ATHALYE, Melarkode Subbaraman RAMAKRISHNAN, Tania CROMBET RAMOS, Kalet LEÓN MONZÓN, Mayra RAMOS SUZARTE
-
Publication number: 20230018364Abstract: The present invention is related to the branches of Biotechnology and Medicine. It particularly describes highly concentrated and stable pharmaceutical formulations of the humanized monoclonal antibody nimotuzumab at a concentration within the range from 50 to 200 mg/mL. The low viscosity of these solutions allow for their administration by the subcutaneous or intramuscular routes in the treatment of cancer. These formulations are stable in both their liquid and lyophilized forms.Type: ApplicationFiled: December 10, 2020Publication date: January 19, 2023Inventors: Yaiko Saddan HERNÁNDEZ TERRERO, Olga Lidea FERNÁNDEZ SÁEZ, Julio Felipe SANTO TOMÁS POMPA, Mercedes CEDEÑO ARIAS, Kathya RASHIDA DE LA LUZ HERNÁNDEZ, Tammy BOGGIANO AYO, Kalet LEÓN MONZÓN, Adolfo CASTILLO VITLOCH
-
Publication number: 20220152107Abstract: The present invention describes a method for obtaining lymphoid cells having a desired phenotype for adoptive transfer therapies useful for the treatment of cancer. Especially, this invention is related to strategies for inducing preferential signaling through the intermediate affinity IL-2 receptor in order to expand the cells with a desired central memory phenotype. The method of the present invention is useful for obtaining tumor-infiltrating lymphocytes, TCR or chimeric antigen receptor engineered T cells for the treatment of cancer.Type: ApplicationFiled: March 9, 2020Publication date: May 19, 2022Inventors: Kalet LEÓN MONZÓN, Magela MONTALVO BEREAU, George COUKOS, Melita IRVING, Elisabetta CRIBIOLI, Yaquelin ORTIZ MIRANDA, Ángel de Jesús CORRIA OSORIO
-
Publication number: 20210238246Abstract: The present invention describes fusion proteins based on cytokines, called bi-cytokines (BC), specifically formed by the binding of an IL2 agonist mutein with a type I interferon (IFN), linked by an Fc region of a mutant human IgG1 and a connector peptide. The combination of an IL2 agonist mutein and a type I IFN in the structure of the bi-cytokines gives surprising immunoregulatory properties to these molecules and a superior therapeutic effect than that of parental cytokines, or their combination, which makes them attractive and novel molecules for the treatment of cancer. Pharmaceutical compositions comprising as an active ingredient the fusion proteins object of this patent are also described.Type: ApplicationFiled: March 5, 2019Publication date: August 5, 2021Applicant: Centro de Inmunologia MolecularInventors: Tays HERNÁNDEZ GARCíA, Maura Lisett RÁBADE CHEDIAK, Kalet LEÓN MONZÓN, Circe MESA PARDILLO, Luis Enrique FERNÁNDEZ MOLINA, Giselle HEVIA HERNÁNDEZ
-
Publication number: 20210002375Abstract: This invention provides new antibodies (Ab) and fragments that recognize the extracellular region of the human epidermal growth factor receptor (hEGFR) with a higher affinity than the Ab nimotuzumab, thus been able to recognize more efficiently lines with medium expression of EGFR. The present invention also relates to pharmaceutical compositions comprising as active principle the disclosed Abs and fragments and their use in the therapy of tumors with EGFR expression. In addition, it relates to the use of the Abs and fragments disclosed linked to a radioisotope or fluorophore for the localization of EGFR positive tumors. Additionally, the Abs and fragments disclosed can be used in the directionalization of the immune response to EGFR positive tumor cells when they are fused to protein or protein domains of immunological interest.Type: ApplicationFiled: November 20, 2018Publication date: January 7, 2021Inventors: Yaima Tundidor Cabado, Gertrudis Rojas Dorantes, Kalet Leon Monzon
-
Publication number: 20190315826Abstract: The present invention relates to the field of Biotechnology, particularly to a method based on the introduction of a single mutation in the genes encoding the human IL-2 and the muteins derived thereof that results in increased secretion levels in different hosts without affecting their biological functions. In particular, these mutations are based on a non-conservative change in the amino acid located in position 35 in the primary sequence of human IL-2, preferably the substitutions are K35E, K35D and K35Q. Another object of the present invention are the expression systems used to obtain both the recombinant human IL-2 and the muteins derived thereof using the method described in this invention. The above-mentioned method is useful to improve the production efficiency of the recombinant human IL-2 and the muteins derived thereof both at laboratory and industrial scales.Type: ApplicationFiled: November 10, 2017Publication date: October 17, 2019Inventors: GERTRUDIS ROJAS DORANTES, KALET LEÓN MONZÓN, TANIA CARMENATE PORTILLA
-
Patent number: 9790279Abstract: The present invention relates to pharmaceutical compositions for the treatment of malignant tumors. Particularly those tumors that express EGFR and GM3 N-glycolyl ganglioside targets to enhance the therapeutic effect produced by separated therapies against these targets. The pharmaceutical compositions of the invention include antibodies and/or vaccines against each of the targets. Additionally the present invention relates to methods for applying the compositions of the invention.Type: GrantFiled: December 4, 2012Date of Patent: October 17, 2017Assignee: CENTRO DE IMMUNOLOGIA MOLECULARInventors: Adys González Palomo, Adriana Carr Perez, Kalet León Monzón, Rancés Blanco Santana, María del Carmen Barroso Alvarez, Amparo Emilia Macías Abraham, José Enrique Montero Casimiro
-
Patent number: 9701730Abstract: The present invention relates to the field of Biotechnology and more particularly to the mutated polypeptides of TGF? molecule whose primary sequence has a high homology with the sequence of human TGF?. These muteins lose their ability to interact with ALK5 but maintain their ability to interact with other receptors that are part of the receptor complex (T?RII and T?RIII). They have the property of antagonizing the signaling of all natural variants of TGF? ligands, dependent of ALK5 recruitment in the receptor complex, and have significant immunomodulatory effects. The present invention relates to pharmaceutical compositions comprising as active principle the polypeptides or fusion proteins disclosed and their use thereof given their modulating effect on the immune system in diseases such as cancer, diseases accompanied by fibrosis and chronic infectious diseases.Type: GrantFiled: October 30, 2013Date of Patent: July 11, 2017Assignee: Centro De Inmunologia MolecularInventors: Ángel de Jesús Corria Osorio, Kalet León Monzón, Tania Carmenate Portilla, Amaury Pupo Meriño, Saumel Pérez Rodríguez
-
Patent number: 9206243Abstract: The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases.Type: GrantFiled: November 10, 2011Date of Patent: December 8, 2015Assignee: CENTRO DE IMMUNOLOGIA MOLECULARInventors: Kalet León Monzón, Tania Carmenate Portilla, Saumel Pérez Rodriguez, Neris Michel Enamorado Escalona, Agustin Bienvenido Lage Dávila
-
Publication number: 20150284441Abstract: The present invention relates to the field of Biotechnology and more particularly to the mutated polypeptides of TGF? molecule whose primary sequence has a high homology with the sequence of human TGF?. These muteins lose their ability to interact with ALK5 but maintain their ability to interact with other receptors that are part of the receptor complex (T?RII and T?RIII). They have the property of antagonizing the signaling of all natural variants of TGF? ligands, dependent of ALK5 recruitment in the receptor complex, and have significant immunomodulatory effects. The present invention relates to pharmaceutical compositions comprising as active principle the polypeptides or fusion proteins disclosed and their use thereof given their modulating effect on the immune system in diseases such as cancer, diseases accompanied by fibrosis and chronic infectious diseases.Type: ApplicationFiled: October 30, 2013Publication date: October 8, 2015Applicant: CENTRO DE INMUNOLOGIA MOLECULARInventors: Ángel de Jesús Corria Osorio, Kalet León Monzón, Tania Carmenate Portilla, Amaury Pupo Meriño, Saumel Pérez Rodríguez
-
Publication number: 20140363494Abstract: The present invention relates to pharmaceutical compositions for the treatment of malignant tumors. Particularly those tumors that express EGFR and GM3 N-glycolyl ganglioside targets to enhance the therapeutic effect produced by separated therapies against these targets. The pharmaceutical compositions of the invention include antibodies and/or vaccines against each of the targets. Additionally the present invention relates to methods for applying the compositions of the invention.Type: ApplicationFiled: December 4, 2012Publication date: December 11, 2014Inventors: Adys González Palomo, Adriana Carr Perez, Kalet León Monzón, Rancés Blanco Santana, María del Carmen Barroso Alvarez, Amparo Emilia Macías Abraham, José Enrique Montero Casimiro
-
Publication number: 20140314709Abstract: The present invention relates to polypeptides which share primary sequence with human IL-2, except for several amino acids that have been mutated. The mutations introduced substantially reduce the ability of these polypeptides to stimulate in vitro and in vivo regulatory T cells (T CD4+CD25+FoxP3+) and make them more effective in the therapy of murine transplantable tumors. Also includes therapeutic uses of these mutated variants, used alone or in combination with vaccines for the therapy of diseases such as cancer or infections where the activity of regulatory T cells (Tregs) is relevant. In another aspect the present invention relates to pharmaceutical compositions comprising as active principle the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptidess and pharmaceutical compositions disclosed due to their modulating effect of the immune system on diseases like cancer and chronic infectious diseases.Type: ApplicationFiled: November 10, 2011Publication date: October 23, 2014Applicant: CENTRO DE INMUNOLOGIA MOLECULARInventors: Kalet León Monzón, Tania Carmenate Portilla, Saumel Pérez Rodríguez, Neris Michel Enamorado Escalona, Agustín Bienvenido Lage Dávila
-
Patent number: 8759486Abstract: The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.Type: GrantFiled: November 26, 2010Date of Patent: June 24, 2014Assignee: Centro de Inmunologia MolecularInventors: Kalet León Monzón, Tania Carmenate Portilla, Karina García Martínez, Augustín Bienvendo Lage Davila, Samuel Pérez Rodríguez, Diamile González Roche, Gabriel Márquez Perera
-
Publication number: 20120315245Abstract: The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.Type: ApplicationFiled: November 26, 2010Publication date: December 13, 2012Applicant: CENTRO DE INMUNOLOGIA MOLECULAR (CIM)Inventors: Kalet León Monzón, Tania Carmenate Portilla, Karina García Martínez, Agustin Bienvendo Lage Davila, Samuel Pérez Rodríguez, Diamile González Roche, Gabriel Márquez Perera